No Data
No Data
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)
Buy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical Prospects
Prelude Therapeutics | 10-Q: Quarterly report
Express News | Prelude Therapeutics Inc - Current Cash Runway Into 2026
Express News | Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
No Data